P08.09 Axitinib for the treatment of patients with recurrent glioblastoma, final results from a randomized phase II clinical trial

BACKGROUND: vascular endothelial growth factor receptor (VEGFR) signal transduction mediates glioblastoma (GB) associated neo-angiogenesis. The AXIG trial (NCT01562197) is a randomized clinical trial that initially investigated the activity of axitinib as a monotherapy (AXI-arm) versus physicians be...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Duerinck, J., Du Four, S., Bouttens, F., Verschaeve, V., Andre, C., Van Fraeyenhove, F., Chaskis, C., D’haene, N., Salmon, I., Neyns, B.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2016
Materias:
P08 Glioblastom and Anaplastic gliomas
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782638/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.142
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares